Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 8

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 8
---
us, including, among other things, adoption of the Business Combination Agreement and approval of the transactions contemplated by the Business Combination Agreement, including: (a) the merger of Liminatus Merger Sub with and into Liminatus, with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of ParentCo, and (b) simultaneously with the Liminatus Merger, the merger of SPAC Merger Sub with and into Iris, with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of ParentCo, and the issuance of the Company’s securities as consideration thereunder.

On the Closing Date, (i) Iris effected the SPAC Merger by filing a certificate of merger with the Secretary of State of the State of Delaware in accordance with the applicable provisions of the DGCL, and (ii) the Company effected the Liminatus Merger by filing a certificate of merger with the Secretary of State of the State of Delaware in accordance with the applicable provisions of the Delaware Limited Liability Company Act, with each of the Mergers being consummated and effective simultaneously as of April 30, 2025.

In connection with the Business Combination, the Company filed an amended and restated certificate of incorporation, which, among other things, changed the Company’s name to “Liminatus Pharma, Inc.”

On the Closing Date, the Business Combination, among other transactions contemplated by the Business Combination Agreement, was completed (the “Closing”).

Effect of the Business Combination on Existing Iris Equity

Pursuant to the Business Combination Agreement:

<div align='center'>7</div>

| (i) | immediately prior to the effective time of the Mergers, every issued and outstanding Iris Unit automatically separated into its constituent parts and the holder thereof were deemed to hold one share of Iris Class A Common Stock and one-fourth of one whole redeemable warrant that was included as part of each Iris Unit; |

| (ii) | at the Effective Time, each issued and outstanding Iris Class A Share converted automatically into one share of ParentCo Common Stock, following which all Iris Class A Shares were automatically cancelled and ceased to exist and be outstanding; |

| (iii) | at the Effective Time, each issued and outstanding Public Warrant, in accordance with the terms of the Warrant Agreement, immediately and automatically converted into the right to purchase shares of ParentCo Common Stock on the same terms and conditions as are set forth in the Warrant Agreement; |

| (iv) | at the Effective Time